Premium
IgE, anti‐IgE, and allergic keratoconjunctivitis ‐ part 2
Author(s) -
CHIAMBARETTA F
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.3272.x
Subject(s) - omalizumab , vernal keratoconjunctivitis , medicine , immunoglobulin e , tacrolimus , dermatology , allergy , asthma , immunology , refractory (planetary science) , allergic conjunctivitis , monoclonal antibody , anaphylactic reactions , anaphylaxis , antibody , transplantation , physics , astrobiology
Vernal and atopic keratoconjunctivis (VKC, AKC) are severe types of ocular allergy, characterized by acute and chronic corneoconjunctival inflammation that may lead to visual sequelae. Although topical immunosuppressive drugs such as cyclosporine and tacrolimus are usually effective, some severe may be refractory. Omalizumab is a monoclonal anti IgE antibody, administered systematically and authorized for severe asthma. We will report our clinical experience of omalizumab in AKC and VKC patients, and will also detail a review of the literature.